Balyasny Asset Management
MGNX icon

Balyasny Asset Management’s MacroGenics MGNX Stock Holding History

Balyasny Asset Management’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,000
Closed -$74K – 3105
2022
Q2 		$74K Buy
+25,000
New +$131K ﹤0.01% 2316

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's MGNX Position: Q2 2024 in Review

Balyasny Asset Management sold out of MacroGenics (MGNX) in Q2 2024, closing a stake of 58,997 shares — an estimated $868K sold.

Balyasny Asset Management first reported a position in MGNX in Q2 2015 and held it in 18 quarters. The position peaked at $13M in Q3 2015. 146 funds tracked by Wall St. Rank hold MGNX as of Q2 2024.

  • Balyasny Asset Management reported no remaining MacroGenics position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 58,997 MacroGenics shares in Q2 2024, an estimated $868K.
  • Balyasny Asset Management first reported a position in MacroGenics in Q2 2015 and held it in 18 quarters.
  • Balyasny Asset Management's MacroGenics position peaked at $13M in Q3 2015.
  • 146 funds tracked by Wall St. Rank held MacroGenics as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.